Product Description
Mechanisms of Action: 5-HT2A Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: ErgoNex Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Scleroderma, General
Phase 2: Scleroderma, General|Scleroderma, Diffuse|Hypertension, Pulmonary|Fibromyalgia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| INC-6602 | N/A |
Not yet recruiting |
Obstetric Labor, Premature |
2021-09-30 |
|
| ECU-PNH-III | N/A |
Not yet recruiting |
Obstetric Labor, Premature|Infant Nutrition Disorders|Child Nutrition Disorders |
2019-01-31 |
|
| TERGISS | P3 |
Terminated |
Scleroderma, General |
2018-06-05 |
|
| TERPAH | P2 |
Completed |
Hypertension, Pulmonary |
2011-09-20 |